Risedronic Acid

Risedronic Acid

SCHEMBL2324758

NCC(=O)O.NCC(=O)O.O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

FDPS

The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FDPS known ✓ P14324 11/20 0.81
BTN3A1 O00481 1/20 0.81
PDE3A Q14432 1/20 0.81
NAPRT Q6XQN6 1/20 0.50
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 1/20 0.49
HIF1A Q16665 1/20 0.49
GGPS1 O95749 2/20 0.46
TBXAS1 P24557 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Risedronic Acid SCHEMBL2324063 1.00 FDPS (0.81) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL18378 0.90 FDPS (1.00) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL29362587 0.90 FDPS (1.00) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL2115054 0.88 FDPS (0.97) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL4989214 0.88 FDPS (0.97) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL3170751 0.88 FDPS (0.97) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL3771017 0.88 FDPS (0.97) FDPSBTN3A1PDE3ACYP1A2CYP3A4
Risedronic Acid SCHEMBL2115050 0.88 FDPS (0.97) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL22720092 0.87 FDPS (0.94) FDPSBTN3A1PDE3ANAPRTCYP1A2
Risedronic Acid SCHEMBL22720090 0.87 FDPS (0.94) FDPSBTN3A1PDE3ANAPRTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3362071-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY Grünenthal GmbH (DE) 2018-08-22 EP disclosed
WO-2017049294-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2017-03-23 WO disclosed
EP-2531200-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY Thar Pharmaceuticals, Inc. (US) 2012-12-12 EP disclosed
WO-2011097269-A1 CRYSTALLIZATION METHOD AND BIOAVAILABILITY THAR PHARMACEUTICALS, INC. (US) 2011-08-11 WO disclosed